%0 Journal Article
%T Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
%A Abhijit Gadkari
%A Andreas Wollenberg
%A Bolanle Akinlade
%A Eric L. Simpson
%A Gianluca Pirozzi
%A Jean-Philippe Lacour
%A Jonathan I. Silverberg
%A Laurent Eckert
%A Margitta Worm
%A Marius Ardeleanu
%A Neil M.H. Graham
%J Journal of Allergy and Clinical Immunology
%D 2018
%R 10.1016/j.jaci.2017.12.418
%X Dupilumab, a fully human anti-IL-4R¦Á mAb, inhibits signaling of IL-4 and IL-13, key
drivers of type 2/Th2 immune diseases. Dupilumab is approved by the FDA with or without
topical corticosteroids for treatment of adults with moderate-to-severe AD. We report
on efficacy and safety of dupilumab in adults with moderate-to-severe AD with or without
patient-reported comorbid food allergy (FA) in two pooled phase 3 monotherapy trials
(LIBERTY AD SOLO 1&2: NCT02277743; NCT02277769).
%U https://www.jacionline.org/article/S0091-6749(17)32318-7/abstract